Ironwood Pharmaceuticals reported $113.04M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Almirall EUR 602.71M 55.09M Jun/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
Ardelyx USD 120.88M 26.41M Jun/2026
Astellas Pharma JPY 629.95B 10.96B Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Charles River Laboratories USD 982.7M 17.3M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 32.83M 12.03M Jun/2026
Moderna USD 1.31M 98.69M Sep/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Pacira USD 176.65M 15.75M Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Takeda JPY 1.19T 32.9B Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024